Cetuximab in previously treated colorectal cancer

Clinical Colorectal Cancer

Volumn 5, Issue SUPPL. 1, 2005, Pages

  Starling, Naureen ^a   Cunningham, David ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Epidermal growth factor receptor; Irinotecan; Monoclonal antibody; Oxaliplatin; Targeted therapy

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BIOLOGICAL MARKER; CAMPTOTHECIN; CETUXIMAB; DRUG DERIVATIVE; EPIDERMAL GROWTH FACTOR RECEPTOR; IRINOTECAN; MONOCLONAL ANTIBODY; OXALIPLATIN; PLATINUM COMPLEX;

COLORECTAL TUMOR; DRUG ANTAGONISM; HUMAN; METHODOLOGY; PATIENT SELECTION; REVIEW; SALVAGE THERAPY;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL MARKERS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; HUMANS; ORGANOPLATINUM COMPOUNDS; PATIENT SELECTION; RECEPTOR, EPIDERMAL GROWTH FACTOR; SALVAGE THERAPY;

EID: 21744435122     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2005.s.004     Document Type: Article

References (38)

1. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22:23-30.
2. Tournigand C, Andre T, Achille E, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22:229-237.
3. Messa C, Russo F, Caruso MG, et al. EGF, TGF-alpha, and EGF-R in human colorectal adenocarcinoma. Acta Oncol 1998; 37:285-289.
4. Porebska I, Harlozinska A, Bojarowski T. Expression of the tyrosine kinase activity growth factor receptors (EGFR, ERB B2, ERB B3) in colorectal adenocarcinomas and adenomas. Tumour Biol 2000; 21:105-115.
5. Mayer A, Takimoto M, Fritz E, et al. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and Mdr gene expression in colorectal cancer. Cancer 1993; 71:2454-2460.
6. Ogiso H, Ishitani R, Nureki O, et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains. Cell 2002; 110:775-787.
7. Marmor MD, Skaria KB, Yarden Y. Signal transduction and oncogenesis by ErbB/HER receptors. Int J Radiat Oncol Biol Phys 2004; 58:903-913.
8. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2001; 2:127-137.
9. Arteaga C. Targeting HER1/EGFR: a molecular approach to cancer therapy. Semin Oncol 2003; 30(3 Suppl 7):3-14.
10. Milas L, Mason K, Hunter N, et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res 2000; 6:701-708.
11. Baselga J, Norton L, Masui H, et al. Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies. J Natl Cancer Inst 1993; 85:1327-1333.
12. Fan Z, Baselga J, Masui H, et al. Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well established A431 cell xenografts. Cancer Res 1993; 53:4637-4642.
13. Ciardiello F, Bianco R, Damiano V, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999; 5:909-916.
14. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003; 21:2787-2799.
15. Prewett MC, Hooper AT, Bassi R, et al. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMCC225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002; 8:994-1003.
16. Rubin MS, Shin DM, Pasmantier M, et al. Monoclonal antibody (MoAb) IMC-C225, an anti-epidermal growth factor receptor (EGFr) for patients (pts) with EGFr-positive tumors refractory to or in relapse from previous therapeutic regimens. Proc Am Soc Clin Oncol 2000; 19:474a (Abstract #1860).
17. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000; 18:904-914.
18. Albanell J, Codony-Servat J, Rojo F, et al. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. Cancer Res 2001; 61:6500-6510.
19. Shin DM, Donato NJ, Perez-Soler R, et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001; 7:1204-1213.
20. Saltz LB, Rubin MS, Hochster H, et al. Cetuximab (IMC-C225) plus irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR). Proc Am Soc Clin Oncol 2001; 20:3a (Abstract #7).
21. Saltz LB, Meropol NJ, Loehrer PJ, et al. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004; 22:1201-1208.
22. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337-345.
23. Cunningham D, Humblet Y, Sienna S, et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan refractory, metatstatic colorectal cancer (MCRC). Proc Am Soc Clin Oncol 2003; 22:252 (Abstract #1012).
24. Gustafson NF, Saltz LB, Cunningham D, et al. Safety profile of cetuximab in patients with metastatic colorectal cancer. Late-breaking Abstract from the 2004 Annual Meeting of ASCO. Proc Am Soc Clin Oncol 2004; 22(suppl):237.
25. Lenz HJ, Mayer RJ, Gold PJ, et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin. Proc Am Soc Clin Oncol 2004; 23:248 (Abstract #3510).
26. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005; 23:1803-1810.
27. Saltz LB, Kies S, Abbruzzese JL, et al. The presence and intensity of the cetuximab-induced acne-like rash predicts increased survival in studies across multiple malignancies. Proc Am Soc Clin Oncol 2003; 22:204 (Abstract #817).
28. Anido J, Matar P, Albanell J, et al. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells. Clin Cancer Res 2003; 9:1274-1283.
29. Tabernero J, Rojo F, Jiménez E, et al. A phase I pharmacokinetic (PK) and serial tumor and skin pharmacodynamic (PD) study of weekly, every 2 weeks or 3 weeks 1-hour (h) infusion of EMD72000, an humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody in patients (p) with advanced tumors known to overexpress the EGFR. Eur J Cancer 2002; (suppl 7):S69-S70.
30. Rojo F, Tabernero J, Van Cutsem E, et al. Pharmacodynamic studies of tumor biopsy specimens from patients with advanced gastric carcinoma undergoing treatment with gefinitib (ZD1839). Proc Am Soc Clin Oncol 2003; 22:191 (Abstract #764).
31. Zhang W, Yun J, Press OA, et al. Association of cyclin D1 (CCND1) gene A870G polymorphism and clinical outcome of EGFR-positive metastatic colorectal cancer patients treated with epidermal growth factor receptor (EGFR) inhibitor cetuximab (C225). Proc Am Soc Clin Oncol 2004; 23:250 (Abstract #3518).
32. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004; 350:2129-2139.
33. Badarinath S, Mitchell P, Jennis A, et al. Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): preliminary safety analysis of a randomized phase III trial. Proc Am Soc Clin Oncol 2004; 23:253 (Abstract #3531).
34. Tabernero JM, Van Cutsem E, Sastre J, et al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR). preliminary results. Proc Am Soc Clin Oncol 2004; 23:248 (Abstract #3512).
35. Rougier P, Raoul JL, Van Laethem JL, et al. Cetuximab+FOLFIRI as first-line treatment for metastatic colorectal cancer CA. Proc Am Soc Clin Oncol 2004; 23:253 (Abstract #3513).
36. Folprecht G, Lutz M, Schoeffski P, et al. Cetuximab/irinotecan/high-dose- 5-fluorouracil/leucovorin in the first-line therapy of metastatic colorectal cancer. Late-breaking Abstract from the 2004 Annual Meeting of ASCO. Proc Am Soc Clin Oncol 2004; 22(suppl):283.
37. Ciardiello F, Bianco R, Damiano V, et al. Antiangiogenic and antitumor activity of anti-epidermal growth factor receptor C225 monoclonal antibody in combination with vascular endothelial growth factor antisense oligonucleotide in human GEO colon cancer cells. Clin Cancer Res 2000; 6:3739-3747.
38. Saltz LB, Lenz H, Kindler H, et al. Interim report of randomized phase II trial of cetuximab/bevacizumab/irinotecan (CBI) versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer. Presented at: The 2005 Gastrointestinal Cancers Symposium: Multidisciplinary Approaches to Gastrointestinal Malignancies and Premalignancies; January 27-29, 2005; Hollywood, FL. Abstract #169b.